Ondansetron for

Johnson BA, Ait-DaoudN Neuropharmacological treatments for alcoholism scientific basis and clinical findings. Psychopharmacology (Berl) 149 327—344, 2000 Johnson BA, Roache JD, Javors MA, et al Ondansetron for reduction of drinking among biologically predisposed alcoholic patients a randomized controlled trial. 

Johnson BA, Roache JD, Javors MA, et al Ondansetron for reduction of drinking among biologically predisposed alcoholic patients a randomized controlled trial. 

As described above, ondansetron has potent and highly selective antagonist properties at the 5-HT3-receptor [7]. The selectivity of action of ondansetron for the 5-HT3 receptor has been demonstrated using a number of in vitro preparations which respond to activation of a number of different neurotransmitter receptors. The selectivity ratio for ondansetron on 5-HT3-recep-tors compared with other receptor types is greater than 1000. In animals and in man, ondansetron has no overt actions on cardiovascular parameters and there are no effects on normal behaviour [7]. 

Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy Italian Group for Antiemetic Research. N Engl J Med 2000 342 1554-1559. 

Sullivan CA, Johnson CA, Roach H, Martin RW, et al. A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 1996 174 1565-1568. 

Ergonovine for Alzheimer s disease Methysergide for acute migraine headache Ondansetron for acute migraine headache Ranitidine for Parkinson s disease Which of the following is most useful in the treatment of hyperprolactinemia ... 

Study and classification of serotonin receptors has resulted in the design and synthesis of highly selective medicines such as Sumatriptan, for the treatment of migraine, Ondansetron for the suppression of the nausea and vomiting caused by cancer chemotherapy and radiotherapy, and Alosetron for treatment of irritable bowel syndrome. 

AlAbood RM, Talegaonkar S, Tariq M, and Ahmad FJ. (2013). Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting. Colloids Surface B Biointerfaces, 101, 143-151. 

Rung G Claybon L, Hord A, et aL The intravenous ondansetron for postsurgical opioid-induced nausea and vomiting. Anesth Analg 1997 84 832-838. 

A combined analysis of the two studies demonstrates that both aprepitant doses (40 and 125 mg) improved protection against nausea and vomiting and reduced the need for rescue therapy, compared with ondansetron. The 40 mg aprepitant dose also was found to be superior to ondansetron for the prevention of nausea, vomiting, and the need to use rescue therapy in the same patient. 

Gan T, et al. A randomized, double-blind comparison of the NKl-antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Ana/g2007 104 1082-1089. 

Yun MJ, Kim YH, Kim AR. Comparison of azasetron and ondansetron for preventing postoperative nausea and vomiting in patients undergoing gynaecological laparoscopic surgery. Yonsei Med J 2010 51 88-92. 

---